Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.48−0.03 (-5.42%)
Close on Nov 17, 2026Market cap $73.93MP/E –Yield –
Coherus Oncology EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Coherus Oncology's EV/EBITDA was 3.3× on Apr 30, 2021, against 8.9× a year earlier.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2021 | Apr 30, 2021 | 3.3× | −1.5 |
| 2020 | Dec 31, 2020 | 4.8× | −226.3 |
| 2019 | Dec 31, 2019 | 231.1× | – |
See a number that looks wrong?